WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) – Aileron Therapeutics (NASDAQ: ALRN) today announced that Manuel Aivado, MD, Ph.D., President and CEO, will give a corporate presentation at the 2021 HC Wainwright Global Life Sciences Conference, taking place March 9 – 10, 2021. Dr. Aivado’s presentation will provide an overview of the upcoming Aileron test at Phase 1b under control placebo of ALRN-6924 in patients with non-small cell p53-mutated advanced lung cancer, expected to begin in the second quarter of 2021, including an extension of the company’s target registration announced earlier in the year. week.
Webcast of the show will be available upon request under the Investors and Media section of the Aileron website at https://investors.aileronrx.com/ starting March 9, 2021 at 7:00 am EST. A replay of the webcast will be posted on the Aileron website for 90 days after the event.
About Aileron Therapeutics
Aileron is a clinical-grade biopharmaceutical company that aims to allow patients to fight cancer without the fear or burden of side effects caused by chemotherapy. We believe that elective chemoprotection has the potential to fundamentally transform chemotherapy like anesthesia-modified surgery.
ALRN-6924, our first-class MDM2 / MDMX dual inhibitor activating p53, is the only chemoprotective agent reported in clinical development to employ a biomarker strategy, in which we will focus specifically on its treating patients with p53-mutated cancers. Our targeted strategy is designed to protect a wide variety of healthy cells throughout the body from chemotherapy while ensuring that we do not protect cancer cells. As a result, healthy cells are protected from chemotherapeutic destruction while chemotherapy continues to kill cancer cells. In addition to reducing or eliminating a number of side effects caused by chemotherapy, ALRN-6924 can also improve patients’ quality of life and help them adopt better chemotherapy. Improved tolerance can lead to reduced dose or delay of chemotherapy and the potential for better efficacy.
Our vision is to provide chemoprotection to patients with p53-mutated cancers, which represent approximately 50% of cancer patients, regardless of cancer type or chemotherapy. Visit us at aileronrx.com to learn more.